CDKN2A and cancer: Similarly, a study of testicular cancer survivors treated with chemotherapy found higher p16INK4a expression in 16 cancer survivors (aged 24–54 years) compared to the expression in 16 age-matched controls without a history of cancer (p-value = 0.048) [54].